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recurrent disease, by improving sensitivity 
of diagnostic tests, such as Tg (thyroglobu-
lin) measurements or whole-body RAI (ra-
dioiodine) scans. Additional ablation goals 
are adjuvant therapy, by targeting potential 
residual disease with improvement of dise-
ase-free survival; and therapy, which may 
IntroductIon
Total, or near-total, thyroidectomy followed 
by 131I radioiodine ablation represents the 
gold standard treatment for differentiated 
thyroid cancer. The main purpose of per-
forming ablation is elimination of normal 
thyroid cells, which facilitates detection of 
Corresponding author
Filippo Cipriani
filippo.cipriani@genzyme.com
Disclosure
The study was funded and 
conducted by Sanofi Genzyme
AbstrAct
BACKGROUND: Radioiodine ablation is an adjuvant procedure used to treat patients with differentiated thyroid can-
cer. For ablation to be successful, patients must have elevated levels of thyroid stimulating hormone (TSH). This can be 
achieved by withholding thyroid hormone therapy (endogenous stimulation), or by administration of recombinant human 
thyroid stimulating hormone (rhTSH; Thyrogen®; exogenous stimulation) to patients in the euthyroid state.
AIM: To compare the estimated health benefits, cost and cost-effectiveness of TSH stimulation with and without Thyrogen® 
in the Italian setting. 
METHODS: A cost-utility analysis was undertaken to assess the impact of exogenous vs. endogenous TSH stimulation 
before radioiodine remnant ablation of patients with newly diagnosed, well-differentiated papillary or follicular thyroid 
cancer who have undergone total or near-total thyroidectomy. A Markov model was developed to simulate treatment costs 
and health outcomes associated with exogenous and endogenous stimulation in four distinct health states: pre-ablation, 
ablation, post-ablation, and well/recovery. Treatment was stratified by patients who receive high- and low-activity (30-100 
mCi, respectively) in the ablation state. The Italian National Health System perspective was adopted in the base case sce-
nario while the impact of indirect costs was explored in a sensitivity analysis. Costs and quality adjusted life years (QALY) 
specific to each health state were estimated, summarized and converted into a corresponding incremental cost-effectiveness 
ratio (ICER).
RESULTS: We calculated a cost effectiveness ratio of 18,357.18 €/QALY gained whereas the inclusion of indirect cost and 
accident cost produced reductions of the ICER to € 14,609.51 and € 15,515.26 per QALY, respectively. Finally, all results 
in the sensitivity analysis are below the lower bound of national and international cost- effective threshold.
CONCLUSION: Thyrogen® represents a cost-effective option for patients with differentiated thyroid cancer who under-
went total or near-total thyroidectomy in Italy. Our findings are consistent with other cost-utility analyses. 
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trials [2,5,9] patients with aggressive types of 
thyroid cancer or distant metastasis were not 
included in the model.
The local healthcare payer perspective was 
adopted in the base case scenario. Never-
theless, the impact of indirect costs (only 
appreciable within the societal perspective) 
is explored in a sensitivity analysis. In order 
to capture the differential costs and utilities 
associated with the short-term morbidity cau-
sed by induced hypothyroidism the economic 
model has a 17-week time horizon, assuming 
no differences beyond that point, as descri-
bed elsewhere [13].
Model structure
The structure of the Markov model (Figure 
1) is based upon the model originally deve-
loped by Mernagh et al. [13]. Briefly, tre-
atment costs and health outcomes associated 
with exogenous stimulation and endogenous 
stimulation were computed in four distin-
ct health states: pre-ablation (time between 
thyroidectomy and ablation), ablation, post-
ablation (divided into two 4-week periods: 
initial and second post-ablation period), and 
well/recovery. Furthermore, in order to incor-
porate the extended indication of Thyrogen® 
for the use with a range of 30-100 mCi of ra-
dioiodine, treatment is stratified by patients 
who receive high- and low-activity in the 
ablation state. The cycle length of the model 
is one week. Costs and quality adjusted life 
years (QALY) specific to each health state 
were estimated, summarized and converted 
into a corresponding incremental cost-effec-
tiveness ratio (ICER).
Clinical inputs
Local data provided from Italian clinicians 
via a survey of treatment practice (reported in 
Appendix A), were used to tailor the analysis 
to the Italian setting. Based on treatment 
survey responses, ≈40% of patients receive 
30 mCi and ≈60% patients receive 100 mCi 
radioiodine. Consistent with previous eco-
nomic evaluations [12,13], and according to 
the available body of clinical evidence the 
model assumed successful ablation in all the 
patients regardless of the method of prepa-
ration and administered radioiodine activity 
[2,5,9,10].
Length of time between thyroidectomy 
and radioiodine ablation
Since endogenously-stimulated patients can 
undergo ablation only after TSH levels have 
naturally elevated to a suitable level, the in-
terval between thyroidectomy and ablation 
might vary from patient to patient. This will 
be further addressed in the discussion since Figure 1. Simplified model structure
improve disease-free survival in higher risk 
patients [1].
Remnant ablation requires elevated thyroid-
stimulating hormone (TSH) levels which in-
crease radioiodine uptake by residual tissue 
and facilitate an effective ablation. TSH ele-
vation can be achieved by discontinuation of 
thyroxine therapy (thyroid hormone withdra-
wal, THW) for at least 4-5 weeks or by ad-
ministration of recombinant human TSH 
(rhTSH – Thyrogen®). The use of Thyrogen® 
allows the patient to continue T4 therapy, 
thus avoiding the consequence of iatrogenic 
hypothyroidism [2].
The benefits associated with the use of 
Thyrogen® include avoidance of the sym-
ptoms of hypothyroidism, which include 
fatigue, weakness, constipation, depression, 
impaired memory and bodily pain. Recen-
tly, hypothyroidism has been associated with 
cognitive and motor impairments that are li-
kely to constitute hazards in the operation of 
motor vehicles and a public safety risk [3]. 
Avoidance of hypothyroidism via Thyrogen® 
therapy has been found to be associated with 
consequent better health-related quality of 
life, little or no productivity loss and a reduc-
tion in the need for GP visits or medications 
[4]. In addition, use of Thyrogen® has been 
shown to allow a shorter duration of the pre-
ablative period and a faster radioiodine cle-
arance rate [5,6] with the possibility of less 
radiation exposure to non-targeted organs 
and earlier discharge from radioprotective 
wards [7,8].
More importantly, such benefits are achie-
ved with ablation efficacy comparable with 
thyroid hormone withdrawal. This was ini-
tially demonstrated in an international ran-
domized controlled study showing similar 
success rates in exogenous- and endogenous-
stimulated patients [5]. Furthermore, two 
phase III studies (HiLo [9] and ESTIMABL 
[2]) have independently confirmed similar 
efficacy for the two methods of TSH stimula-
tion across two 131I activity levels (30 or 100 
mCi). A meta-analysis performed in 2014 
that included 7 randomized controlled trials 
(RCTs) with a total of 1535 patients came to 
the same conclusion [10].
In 2012, the use of Thyrogen® has been ap-
proved for an 131I dose range of 30-100 mCi 
for postoperative remnant ablation, instead of 
the previous approval of just 100 mCi 131I 
[11]. Due to this change, a pre-existing eco-
nomic model [12,13] was adapted to com-
pare exogenous TSH therapy (Thyrogen®) 
with thyroid hormone withdrawal in the Ita-
lian setting. Unlike all previous adaptations, 
including the most recent one in the Korean 
setting [14], our analysis takes into account 
both high- (100 mCi) and low-activities (30 
mCi) of radioiodine. The aim of this study 
was to compare the estimated health benefits, 
cost and cost-effectiveness of TSH stimula-
tion with and without Thyrogen® in the Ita-
lian setting.
Methods
An Italian cost utility analysis was under-
taken to assess the impact of exogenous vs. 
endogenous TSH stimulation before radio-
iodine remnant ablation of patients with 
thyroid cancer who have undergone total or 
near-total thyroidectomy. Consistent with 
the patient characteristics of the three pivotal 
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trials [2,5,9] patients with aggressive types of 
thyroid cancer or distant metastasis were not 
included in the model.
The local healthcare payer perspective was 
adopted in the base case scenario. Never-
theless, the impact of indirect costs (only 
appreciable within the societal perspective) 
is explored in a sensitivity analysis. In order 
to capture the differential costs and utilities 
associated with the short-term morbidity cau-
sed by induced hypothyroidism the economic 
model has a 17-week time horizon, assuming 
no differences beyond that point, as descri-
bed elsewhere [13].
Model structure
The structure of the Markov model (Figure 
1) is based upon the model originally deve-
loped by Mernagh et al. [13]. Briefly, tre-
atment costs and health outcomes associated 
with exogenous stimulation and endogenous 
stimulation were computed in four distin-
ct health states: pre-ablation (time between 
thyroidectomy and ablation), ablation, post-
ablation (divided into two 4-week periods: 
initial and second post-ablation period), and 
well/recovery. Furthermore, in order to incor-
porate the extended indication of Thyrogen® 
for the use with a range of 30-100 mCi of ra-
dioiodine, treatment is stratified by patients 
who receive high- and low-activity in the 
ablation state. The cycle length of the model 
is one week. Costs and quality adjusted life 
years (QALY) specific to each health state 
were estimated, summarized and converted 
into a corresponding incremental cost-effec-
tiveness ratio (ICER).
Clinical inputs
Local data provided from Italian clinicians 
via a survey of treatment practice (reported in 
Appendix A), were used to tailor the analysis 
to the Italian setting. Based on treatment 
survey responses, ≈40% of patients receive 
30 mCi and ≈60% patients receive 100 mCi 
radioiodine. Consistent with previous eco-
nomic evaluations [12,13], and according to 
the available body of clinical evidence the 
model assumed successful ablation in all the 
patients regardless of the method of prepa-
ration and administered radioiodine activity 
[2,5,9,10].
Length of time between thyroidectomy 
and radioiodine ablation
Since endogenously-stimulated patients can 
undergo ablation only after TSH levels have 
naturally elevated to a suitable level, the in-
terval between thyroidectomy and ablation 
might vary from patient to patient. This will 
be further addressed in the discussion since Figure 1. Simplified model structure
it might impact the ward organization. In 
our base case, following recovery from total 
thyroidectomy (inclusive of histology re-
sults), the pre-ablation period (time between 
the decision to perform ablation and the abla-
tion procedure) is about 4 weeks. This inter-
val was calculated based on the answers pro-
vided by the centers involved in the survey 
and reflects our experience as well as real life 
medical practice. In contrast, exogenously-
stimulated patients can experience a much 
shorter pre-ablation preparation period. A 
summary of the duration of each health state 
and the transition probabilities allowing pa-
tients to move from pre-ablation to ablation 
is shown in Appendix B.
Length of stay in radioprotective ward
Consistent with the results of the local tre-
atment survey, the average length of stay 
used in the model was distinguished by the 
radioiodine activity, 2.6 and 3.0 days for 30 
mCi and 100 mCi activities, respectively. 
The length of stay for exogenously and endo-
genously-stimulated patients, in absence of 
local data, were assumed to be the same. This 
assumption is conservative (thus penalizing 
Thyrogen®) since there is a solid body of evi-
dence linking Thyrogen® to a faster clearance 
of 131I after radioiodine ablation [6,15,16], 
leading to a shorter stay in the radioprotecti-
ve ward [7,8,17]. Differences in the length of 
stay, using literature data, were tested in the 
sensitivity analysis. The impact of length of 
stay on modeled outcomes is addressed in the 
discussion.
Utility weights
The time spent in each state was quality adju-
sted using utility weights. Utility weights for 
the pre-ablation and the initial post-ablation 
periods were derived from the SF-36 data 
collected during the initial pivotal RCT [5] 
and transformed into utility weights using 
the SF-6D method [18]. The mean disutili-
ty associated with thyroid hormone therapy 
withdrawal in the endogenously-stimulated 
arm compared to the exogenously-stimulated 
arm is a direct and expected consequence of 
the symptoms associated with hypothyroidi-
sm [5,19].
In order to reflect the disutility that patients 
may feel as a consequence of the ablation 
procedure and the associated time spent in the 
hospital, the ablation utility weights were ba-
sed on those of pre-ablation, with an assumed 
extra disutility of 0.1 applied in each arm. 
The post-ablation period is divided into two 
sequential 4-week periods: in order to cap-
ture a gradual recovery, leading to the well 
health state, the initial period has a lower uti-
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lity than the second. In particular, the utility 
for 0-4 weeks post-ablation was derived di-
rectly from 1-month post-ablation SF-36 data 
from pivotal trial, whereas the utility for 4-8 
weeks post-ablation period was an average of 
the utility weights of the well and initial post-
ablation period [5]. Finally, a conventional 
value of 1 was attributed to the well utility as 
representative of perfect health. As this may 
not be true for all the patients a lower value 
was tested in a sensitivity analysis. A summa-
ry of clinical input and utility weights used in 
the model are reported in Table I.
resource use and cost input
Unit costs applied to resource use are taken 
from the Tariff System of Lombardy [21], 
drug costs were derived from Codifa [22]. 
In the exogenously-stimulated arm the net 
acquisition cost of Thyrogen® plus admini-
stration was taken into account (a visit for 
each of the 2 injections). According to sur-
vey responses, an initial TSH quantification 
test would be performed 4 weeks after T4 
withdrawal, in the case of endogenous sti-
mulation. If the TSH level had not reached 
suitable levels, ablation would be postponed 
by approximately one week. The survey also 
reveals that on average 2.42% and 38.25% 
of endogenously-stimulated patients would 
seek additional treatment from a GP or spe-
cialist, respectively, looking for relief of 
symptoms related to iatrogenic hypothyroi-
dism. Finally, the proportion of radioiodine 
ablation patients taking T3 (liothyronine so-
dium) during the period between their thyroi-
dectomy and radioiodine ablation is also ba-
sed on data from the treatment survey. Unit 
costs incorporated into the economic model 
and source, and total costs per health state in 
each arm are presented in Table II and Table 
III, respectively.
Sensitivity analysis
Individual one-way deterministic sensitivity 
analyses were performed to test the impact 
of key assumptions, and to better understand 
exogenously-stimulated 
arm
endogenously-
stimulated arm Source
30 mCi 100 mCi 30 mCi 100 mCi
Patient (%) 40 60 40 60 Italian treatment survey
Time between surgery recovery 
and ablation (weeks)
1 4 Clinical opinion (rhTSH) and 
Italian treatment survey
Average length of stay in 
radioprotective hospital ward (days)
2.60 3.00 2.60 3.00 Italian treatment survey and 
Author assumptions
Utility weights
Pre-ablation 0.714 0.548 [5] (week 4 data)
Ablation 0.614 0.448 Assumption (pre-ablation – 0.1)
Initial post-ablation 0.712 0.637 [20] (1-month post-ablation)
Second post-ablation 0.856 0.819 Assumption (average of initial 
post-ablation and well)
Well 1 1 Assumption
Table I. Clinical input and utility weight in the base-case
resource
Unit 
cost (€)
Source
Drug costs
Radioiodine ablative activity
 • 30 mCi 140.00 Personnal comunication 
Sant’Orsola hospital
 • 100 mCi 287.00 Personnal comunication
Sant’Orsola hospital
T4 (100 mcg, 1 tablet) 0.06 Codifa [22]
T3 (20 mcg, 1 tablet) 0.07 Codifa [22]
RhTSH (Thyrogen®, 2-vial kit) 720.461 AIFA - Official Gazette [23]
resourse costs
Whole body scan using radioiodine 305.08 92.18.1 [21]
Cost of hospital stay for radioiodine 
ablation (1 day)
700.00 Assumption and [24]
Visit to specialist (endocrinologist 
or radiation oncologist)
22.50 89.7A.8 [21]
Visit to specialist (follow-up visit) 17.90 89.01.8 [21]
Visit to a practice nurse 22.50 Assumption
Visit to a general practitioner (GP) 22.50 Assumption
Visit to GP (follow-up visit) 22.50 Assumption
TSH quantification test (once only) 8.40 90.42.1 [21]
Serum thyroglobulin count 16.35 90.41.5 [21]
Antigen test 13.15 90.54.4 [21]
Daily productivity loss 25.60 See sensitivity analysis
Accident cost 100.00 [4]
Table II. Unit costs used in the model and relative source
1 Official ex-factory price as published in the Official Gazette. The model considers 
purchase cost, after application of mandatory discounts.
Health state
Cost (€)
With Thyrogen® Without Thyrogen®
radioiodine activity = 30 mCi
Pre-ablation 773.92 86.26
Ablation 2,298.66 2,298.26
Initial post-ablation 19.52 19.52
Second post-ablation 1.62 1.62
Well 2.83 1.62
Total 3,096.55 2,407.27
radioiodine activity = 100 mCi
Pre-ablation 773.92 86.26
Ablation 2,729.06 2,728.66
Initial post-ablation 19.52 19.52
Second post-ablation 1.62 1.62
Well 2.83 1.62
Total 3,526.95 2,837.68
Table III. Total costs per health state in each arm of the model
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the main drivers of the economic analysis. In 
particular, we tested the impact of:
 - Including indirect costs, thus adopting a 
societal perspective. This was done ac-
cording to the friction cost methodology:
P= 0.8 × (ω × δ)
where P is the daily productivity loss, ω is 
the daily wage (calculated from total avera-
ge weekly earnings divided by seven days) 
and δ is equal to the unemployment-adjusted 
labor force participation rate. As both ω and 
δ are likely to change substantially from one 
economy to another, the daily productivi-
ty loss is a sensitive variable. For Italy, the 
unemployment rate (12.3%), the labor force 
participation rate (64.4%) and the average 
daily wage (€ 56.65) were obtained from 
ISTAT – (2014). This results in a calculated 
daily productivity loss of € 25.60.
 - Inclusion of accident costs for THW pa-
tients (€ 100 as per 1 month incremental 
risk as in Luster, 2005 [4]).
 - Varying assumptions regarding the diffe-
rence in time spent in the radioprotective 
ward between the two arms due to faster 
clearance of 131I with Thyrogen®, using 
various radiation discharge thresholds 
(see Appendix C).
 - Reducing incremental utility difference 
in the pre-ablation health state and in the 
well health state.
results
Base case
The results presented in Table IV illustrate 
the cost of treatment with Thyrogen® in the 
Italian setting when compared with endo-
genous stimulation of TSH before ablation. 
The incremental cost-effectiveness ratio is 
€ 18,357.18 per each QALY gained, meaning 
that Thyrogen® represents a cost-effective so-
lution.
Sensitivity analysis
The sensitivity analysis identified as the 
most critical variable the potential reduc-
tion in length of stay in the radioprotective 
ward (Figure II). When a 1 day difference 
was assumed for both high- and low-activity 
radioiodine, Thyrogen® dominates endoge-
nous stimulation as it still produced greater 
health gains whilst costing less. In parallel, 
if it is assumed that this difference is seen 
only for the percentage of patients receiving 
high activity 131I, consistent with Mallick 
et al. results [9], we calculated an incremen-
tal cost-effectiveness ratio of € 5,815.46 per 
With 
Thyrogen®
Without 
Thyrogen®
Incremental 
difference
Cost per patient(€) 3,354.04 2,664.46 689.58
Benefit per patient (QALY) 0.281 0.243 0.038
ICER (€/QALY gained) 18,357.18
Table IV. Results of the analysis
QALY. Relatedly, the ICERs are sensitive to 
radioiodine discharge thresholds because of 
differences in length of hospital stay. At all 
considered discharge thresholds (40, 20, 10.8 
and 5.4 mCi, see Appendix C for details) the 
ICER was lower than the base case. Across 
the scenarios tested, the threshold at 20 mCi 
had an ICER of € 9,825.86 per QALY and 
was the most cost-effective result. Sensiti-
vity analyses investigating the inclusion of 
indirect cost and accident cost produced re-
ductions of the ICER to € 14,609.51 and € 
15,515.26 per QALY, respectively.
We further combined the effect of these 
assumptions in a multivariate sensitivity 
analysis (Table V). In particular, the first 
analysis shows the impact of reducing the 
utility score in the well health state as well 
as reducing the utility difference in the pre-
ablation health state by 50%. The QALY gain 
shifts from 0.038 to 0.028 and the ICER in-
creased to € 24,372.27 per QALY. The cost of 
hospitalization had no impact in the base case 
analysis because we assumed that the length 
of stay was only dependent on the activity of 
radioiodine received. The daily cost of hospi-
talization was therefore tested using length 
of stay estimates from Borget et al. [7] at the 
ablation period [5]. Finally, a conventional 
value of 1 was attributed to the well utility as 
representative of perfect health. As this may 
not be true for all the patients a lower value 
was tested in a sensitivity analysis. A summa-
ry of clinical input and utility weights used in 
the model are reported in Table I.
resource use and cost input
Unit costs applied to resource use are taken 
from the Tariff System of Lombardy [21], 
drug costs were derived from Codifa [22]. 
In the exogenously-stimulated arm the net 
acquisition cost of Thyrogen® plus admini-
stration was taken into account (a visit for 
each of the 2 injections). According to sur-
vey responses, an initial TSH quantification 
test would be performed 4 weeks after T4 
withdrawal, in the case of endogenous sti-
mulation. If the TSH level had not reached 
suitable levels, ablation would be postponed 
by approximately one week. The survey also 
reveals that on average 2.42% and 38.25% 
of endogenously-stimulated patients would 
seek additional treatment from a GP or spe-
cialist, respectively, looking for relief of 
symptoms related to iatrogenic hypothyroi-
dism. Finally, the proportion of radioiodine 
ablation patients taking T3 (liothyronine so-
dium) during the period between their thyroi-
dectomy and radioiodine ablation is also ba-
sed on data from the treatment survey. Unit 
costs incorporated into the economic model 
and source, and total costs per health state in 
each arm are presented in Table II and Table 
III, respectively.
Sensitivity analysis
Individual one-way deterministic sensitivity 
analyses were performed to test the impact 
of key assumptions, and to better understand 
exogenously-stimulated 
arm
endogenously-
stimulated arm Source
30 mCi 100 mCi 30 mCi 100 mCi
Patient (%) 40 60 40 60 Italian treatment survey
Time between surgery recovery 
and ablation (weeks)
1 4 Clinical opinion (rhTSH) and 
Italian treatment survey
Average length of stay in 
radioprotective hospital ward (days)
2.60 3.00 2.60 3.00 Italian treatment survey and 
Author assumptions
Utility weights
Pre-ablation 0.714 0.548 [5] (week 4 data)
Ablation 0.614 0.448 Assumption (pre-ablation – 0.1)
Initial post-ablation 0.712 0.637 [20] (1-month post-ablation)
Second post-ablation 0.856 0.819 Assumption (average of initial 
post-ablation and well)
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Table I. Clinical input and utility weight in the base-case
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Drug costs
Radioiodine ablative activity
 • 30 mCi 140.00 Personnal comunication 
Sant’Orsola hospital
 • 100 mCi 287.00 Personnal comunication
Sant’Orsola hospital
T4 (100 mcg, 1 tablet) 0.06 Codifa [22]
T3 (20 mcg, 1 tablet) 0.07 Codifa [22]
RhTSH (Thyrogen®, 2-vial kit) 720.461 AIFA - Official Gazette [23]
resourse costs
Whole body scan using radioiodine 305.08 92.18.1 [21]
Cost of hospital stay for radioiodine 
ablation (1 day)
700.00 Assumption and [24]
Visit to specialist (endocrinologist 
or radiation oncologist)
22.50 89.7A.8 [21]
Visit to specialist (follow-up visit) 17.90 89.01.8 [21]
Visit to a practice nurse 22.50 Assumption
Visit to a general practitioner (GP) 22.50 Assumption
Visit to GP (follow-up visit) 22.50 Assumption
TSH quantification test (once only) 8.40 90.42.1 [21]
Serum thyroglobulin count 16.35 90.41.5 [21]
Antigen test 13.15 90.54.4 [21]
Daily productivity loss 25.60 See sensitivity analysis
Accident cost 100.00 [4]
Table II. Unit costs used in the model and relative source
1 Official ex-factory price as published in the Official Gazette. The model considers 
purchase cost, after application of mandatory discounts.
Health state
Cost (€)
With Thyrogen® Without Thyrogen®
radioiodine activity = 30 mCi
Pre-ablation 773.92 86.26
Ablation 2,298.66 2,298.26
Initial post-ablation 19.52 19.52
Second post-ablation 1.62 1.62
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Total 3,096.55 2,407.27
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discharge threshold for residual radiation of 
20.0 mCi. As shown in Table V, a 50% incre-
ase in cost per day in hospital stay translates 
to a more favorable ICER.
Further multivariate sensitivity analysis was 
undertaken using the discharge threshold for 
residual radiation of 20.0 mCi and amending 
the utility scores. Consistent with previous 
sensitivity analyses the ICERs increased 
when the incremental difference in utility 
was reduced between patients who received 
Thyrogen® and those that received endoge-
nous stimulation. When we simulate what is 
closer to reality, higher cost per hospital stay, 
possibility of earlier discharge and inclusion 
of additional relevant costs such as indirect 
costs and costs associated with accidents, 
Thyrogen® becomes dominant.
In Italy, there is no official cost-effective-
ness threshold. Therefore, as many other au-
thors, we compare our results with a bench-
mark of € 35,000 per QALY, equal to what 
is in use in UK [25] and within the range 
(€ 25,000-40,000 per QALY) recommended 
by the Italian Health Economics Association 
[26]. All results calculated in the sensitivity 
analysis, both one-way and multivariate, are 
below the lower bound of the above mentio-
ned range, supporting Thyrogen® value for 
money.
assumption 1 assumption 2 assumption 3 ICer (€/QalY)
Reducing the incremental utility 
difference in the well health 
state (1 → 0.929)
Reducing the incremental utility 
difference in the pre-ablation health 
state by 50% (0.548 → 0.631)
- 24,372.27
Reducing the incremental utility 
difference in the well health 
state
Reducing the incremental utility 
difference in the pre-ablation health 
state by 50%
Assume difference in LoS and a 
discharge threshold for residual 
radiation = 20 mCi
13,045.50
Inclusion of productivity loss 
(€ 25.60 x 5.5 days)
Inclusion of hypothyroidism accident 
cost (€ 100, as Luster 2005 [4])
- 11,810.53
Assume a discharge threshold for 
residual radiation = 20 mCi
3,376.84
Reducing the cost of 
hospitalization per day by 50%
Assume a discharge threshold for 
residual radiation = 20 mCi
- 14,091.52
Inclusion of productivity loss and 
hypothyroidism accident cost
7,593.78
Variations in utilities
(1 → 0.929; 0.548 → 0.631 )
18,708.89
Increasing the cost of 
hospitalization per day by 50%
Assume a discharge threshold for 
residual radiation = 20 mCi
- 5,560.20
Inclusion of productivity loss and 
hypothyroidism accident cost
Thyrogen® 
dominates THW
Variations in utilities
(1 → 0.929; 0.548 → 0.631 )
7,382.11
Table V. Results of the multivariate sensitivity analysis
LoS = Length of Stay
Figure 2. Results of the univariate sensitivity analysis
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dIscussIon
Thyrogen® avoids daily life disruptions and 
preserves patients’ QoL, whereas thyroid 
hormone withdrawal (THW) has been shown 
to produce a QoL deterioration greater than 
that of heart failure, depression and migraine 
headache [19,27]. The patients’ perspective 
on the desirability of these two alternatives 
is evidenced by the finding that between 86% 
and 97% of interviewed patients favored 
rhTSH over THW [28,29]. As indicated by 
our analysis, the use of Thyrogen® is cost-ef-
fective according to the Italian conventional 
willingness to pay (WTP) thresholds (25,000-
40,000 €/QALY) [26]. To our knowledge this 
is the first study assessing cost-effectiveness 
of Thyrogen® in the Italian setting in patients 
who receive either high- (100 mCi) or low-
activity (30 mCi) radioiodine for remnant 
ablation post-thyroidectomy.
A number of cost-effectiveness analyses of 
Thyrogen® have been conducted previously, 
however it is well known that results can-
not be transferred directly across different 
countries [30]. Our findings are consistent 
with three cost-utility analyses conducted 
using the same model in the German, Ca-
nadian and Korean settings in which ICERs 
were equal to 958 €/QALY, 1,520 Canadian 
$/QALY and 26,697,361 W/QALY, respecti-
vely [12-14].
Most recently, a cost-effectiveness analysis 
performed in France alongside the ESTIMA-
BL trial adopted a longer time horizon and 
considered the consecutive use of Thyrogen® 
in both ablation and follow up procedures 
[31]. Results cannot be directly compared for 
a number of reasons. First, clinical pathways, 
clinicians’ attitudes and/or reimbursement 
mechanism in France might be different from 
Italy and might imply differences in term of 
time and costs. Secondly, as a consequence of 
the longer time horizon adopted in the French 
study (8 +/- 2 months vs 17 weeks), the QoL 
estimates, including both physical and mental 
components, should be compared only in the 
initial 3 months, which are common to both 
simulations. Within such period the QoL sco-
res are quite comparable, however, after this 
point, in the French study there appears to be 
some sort of a prolonged “rebound effect” in 
the THW cohort. Authors did not comment 
on the length and extent of this phenome-
non. In addition, neither the hospital length 
of stay (2.6 vs 2.8 days) nor the sick leave 
time (23 vs. 24 days) appeared to be signi-
ficantly different, in contrast to other retro-
spective reports [7,8]. We remind that length 
of stay is mainly driven by how each nuclear 
medicine ward is organized (number of beds, 
use of beds - 7/7 or just Monday to Friday- 
presence/absence of waiting lists) and, above 
all, by the remuneration system. Culturally in 
Italy there is the common misconception that 
identifies remuneration tariffs such as Dise-
ase Related Groups (DRGs) with real costs. 
Additionally, the DRG applied for ablation 
is calculated on a minimum length of stay 
of two nights, so any earlier discharge, even 
if feasible and desirable, might be internally 
perceived as a productivity loss instead of a 
competitive advantage.
The aim of our research is twofold: on the one 
hand, to support informed decisions with the 
most conservative modelling approach (even 
though less favorable to Thyrogen®), and on 
the other hand, to stimulate constructive de-
bate. Therefore, we decided to run the base 
case scenario under the most conservative as-
sumptions, assuming no difference in length 
of stay. However, in the sensitivity analysis 
we relaxed our hypothesis and assumed an 
earlier discharge for Thyrogen® treated pa-
tients (Borget reported a reduction from 3.5 
to 2.4 days in 2008 [7], whereas Vallejo-Ca-
sas in 2011 documented 1.41 vs. 2.02 days 
[8]); in this scenario, Thyrogen® dominates 
endogenous stimulation by providing better 
QoL outcomes along with cost savings.
In a strict analogy and despite their para-
mount importance, we excluded societal be-
nefits such as productivity gains in the base 
case analysis. This might be counterintuitive 
given the considerable body of evidence sug-
gesting that endogenous stimulation results 
in greater work absenteeism [4,28,32,33]. 
Albeit not in ablation but in the follow up, 
Dietlein et al. [28] reported workday loss 
in 70% of THW patients in follow-up (40% 
with Thyrogen®); Luster et al. [4], back in 
2005, reported a similar figure (65%). In 
both studies the average workday loss was 
between 11 and 12 days (vs. 3 to 4 days in 
case of Thyrogen® use). Borget et al. [32] 
documented a 8.1 days difference in 2007 
whereas the ESTIMABL study [31] reported 
no difference. We speculate that sick leave 
duration is highly dependent of the clinical 
practice: in some cases is set on the basis of 
the disease (thyroid cancer) and not on the 
basis of the treatment. In other words, the 
use of a standard protocol, possibly defined 
on general DTC patients characteristics such 
as age, sex, comorbidities, would totally pre-
vent to appreciate the maintenance of a state 
of wellbeing that is compatible with normal 
productivity in most patients. With the inclu-
sion of such indirect costs, the cost-effecti-
veness of Thyrogen® would further improve 
to 14,695.67 €/QALY when compared with 
endogenous stimulation.
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There are some additional potential Thyro-
gen® advantages that we were not able to ad-
dress in our analysis. The intensity of indivi-
dual symptoms of iatrogenic hypothyroidism 
may vary from patient to patient; however, the 
cognitive, motor and psychological deficits – 
linked to severe hypothyroidism and resulting 
in the impaired ability to operate machinery 
or drive vehicles – might have been underesti-
mated. Driving motor vehicles such as cars or 
motorbikes, should be avoided in the severe 
hypothyroid state because of decreased fine-
motor performance and processing speed, and 
slowed reaction times (braking times were 
increased by 8.0%, equivalent to the motor 
slowing caused by alcohol ingestion at a blood 
concentration of 0.082 g/100 ml; this concen-
tration is above the levels allowed within EU 
for driving) [3]. This is quite relevant since 
driving habits appear to be difficult to change 
in at least 30% of THW cases, irrespectively 
of a strong negative medical advice [4].
The use of Thyrogen® may also improve 
overall ward efficiency, lowering fixed costs 
and halve waiting lists, in analogy of what 
measured in other countries [8,24]. Little is 
known about the real organizational aspects 
related to ablation and isolation rooms in Ita-
lian hospitals, as a consequence of the shorter 
length of stay and the more exact scheduling 
of admissions and discharges.
In conclusion, Thyrogen® represents a good 
treatment option for patients as well as a dif-
ficult exercise for any healthcare professio-
nal operating in a scenario with limited re-
sources: by training, physicians have to keep 
patients from harm, and this should strongly 
advise against inducing hypothyroidism, 
even if temporary, when an alternative, such 
as Thyrogen®, is available. We strongly advo-
cate for future studies about broader aspects 
related to hypothyroidism, since this would 
allow more informed decision making. Re-
trospective analysis on administrative claim 
databases as well as specific patient inter-
views might shed some light whether the 
use of Thyrogen® is able to improve patient 
safety by reducing accidents, either at home 
or related to driving, as well as unscheduled 
use of healthcare resources in the emergency 
departments.
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AppendIx A
The survey (Table IA) was conducted 
amongst clinical experts in endocrinology, 
nuclear medicine and surgery, currently prac-
ticing in Italy. The objective of the survey 
was to establish the current practice of radio-
iodine ablation (both high and low-dose) for 
well differentiated thyroid cancer in those pa-
tients who are endogenously-stimulated prior 
to ablation.
How many newly diagnosed patients undergo ablation each year: Response
100 mCi 889
30mCi 597
What proportion of patients are treated with:  
100 mCi 59.83%
30 mCi 40.17%
What proportions of patients are withheld from T4 replacement therapy straight after their thyroidectomy in 
preparation for scheduled radio-ablation?
 
T4 withheld after surgery 18.33%
T4 withdrawn at a later time 81.67%
What TSH level must be attained before radio-ablation is performed? 30
How many weeks after starting withholding/withdrawal is the patient’s TSH level first measured? 5
If the patient’s TSH level has not reached the required value for ablation when first tested, is it measured again? 1
How many weeks later? 1
What proportion of patients are ablated within the following timeframes in practice  
< 3 weeks 22.11%
3 weeks 12.11%
4 weeks 24.56%
5 weeks 27.33%
6 weeks 13.89%
> 6 weeks 0.00%
Average Pre-ablation Time 3.99
Time left 4.01
Other than time required to reach target TSH, list other factors that influence the delay between surgery & 
ablation:
What proportion of radioiodine ablation patients take T3 (liothyronine sodium) during the period between their 
thyroidectomy and radio-ablation?
50.1%
On average, for how many weeks would T3 be taken by patients? 2.33
What percentage of patients visits their primary care physician to seek treatment or reassurance due to 
symptoms of hypothyroidism?
2.42
What percentage of patients visits their specialist to seek treatment or reassurance due to symptoms of 
hypothyroidism?
38.25
Do you have radio-protective facilities for patient isolation? Y
In your unit, is the patient's external radiation routinely measured after radioiodine ablation? Y
If so, does this measure influence when the patient is discharged from hospital? Y
What is the nearest radiation threshold for discharge?
40 mCi 14.3%
20 mCi 71.4%
10.8 mCi 0.0%
5.4 mCi 14.3%
Following ablation with I131 , what proportion of patients are released from hospital within the following 
timeframes (for 30mCi:
 
Within a day 0.63%
2 days 64.75%
3 days 9.00%
4 days 25.63%
5 days 0.00%
Average 2.60
Table continues>
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Following ablation with I131 , what proportion of patients are released from hospital within the following 
timeframes (for 100mCi:
 
Within a day 0.00%
2 days 28.44%
3 days 43.56%
4 days 27.44%
5 days 0.56%
Average 3.00
If patients are to receive Thyrogen®, what health professionals would be involved in the administration of Thyrogen® 
(nB. administration is by intramuscular injection)?
Practice nurse alone 56%
GP Alone 0%
Specialist alone 11%
Practice nurse and specialist 33%
Practice nurse and GP 0%
Table Ia. Treatment survey conducted amongst clinical experts in endocrinology, nuclear medicine and surgery, currently practicing in Italy
Table continued>
AppendIx b
length of time between thyroidectomy and radioiodine ablation
Health state
exogenous 
stimulation
endogenous 
stimulation
Pre-ablation (time between clinical 
decision and ablation procedure)
1 4
Ablation 1 1
Initial post-ablation period 4 4
Second post-ablation period 4 4
Patient recovered and considered well 7 4
Table IIa. Duration of health states (weeks)
Duration time Transition probabilities
Less than 3 weeks 0.2211
3 weeks 0.1211
4 weeks 0.2456
5 weeks 0.2733
6 weeks 1.0000
Table IIIa. Transition probabilities of endogenous thyroid 
stimulation patients from pre-ablation to ablation states
AppendIx c
Sensitivity analysis
radiation 
threshold (mCi)
radioablative 
dose (mCi)
n
Time spent in hospital/radioprotective ward (days)
exogenous stimulation 
(rhTSH)
endogenous stimulation 
(hypothyroid)
5.4 30 357 0.87 0.99
100 1,484 2.90 3.29
10.8 30 357 0.61 0.78
100 1,484 2.02 2.59
20 30 357 0.33 0.52
100 1,484 1.09 1.73
40 30 357 0.09 0.22
100 1,484 0.29 0.72
Table Va. Time spent in hospital stratified by radiation threshold following radioiodine ablation for patients prepared with exogenous vs. 
versus endogenous stimulation
